VVOS

MKT CAP:$5M

Vivos Therapeutics, Inc.

Market Cap

$5M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$0.90-$1.63 (-64.59%)

Apr 23, 2026

Company Details

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-...

CEO

R. Kirk Huntsman

IPO Date

Dec 11, 2020

Website

vivos.com

Key Metrics TTM

Revenue

$17M

+18.8% YoY

Net Income

-$17M

EPS (Diluted)

-$1.97

Free Cash Flow

-$14M

Revenue / Share

$1.58

Gross Margin

55.7%

Operating Margin

-91.0%

Net Margin

-98.8%

FCF Margin

-83.4%

P/S

0.3x

P/E

—

Earnings Reports

Q3 2025

Nov 19, 2025

$7M+75.7%EPS -$0.49

Q2 2025

Aug 19, 2025

$4M-5.8%EPS -$0.55

Q1 2025

May 15, 2025

$3M-11.8%EPS -$0.45

FY 2024

Mar 31, 2025

$15M+8.9%EPS -$2.22

Q4 2024

Mar 31, 2025

$4M+13.9%EPS -$0.48

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$3M	$3M	-$2M
Q4 20	$3M	$3M	-$6M
Q1 21	$3M	$3M	-$3M
Q2 21	$4M	$4M	-$4M
Q3 21	$5M	$3M	-$6M
Q3 22	$4M	$2M	-$5M
Q2 23	$3M	$2M	-$5M
Q3 23	$3M	$2M	-$3M
Q4 23	$3M	$2M	-$4M
Q1 24	$3M	$2M	-$4M
Q2 24	$4M	$3M	-$2M
Q3 24	$4M	$2M	-$3M
Q4 24	$4M	$2M	-$3M
Q1 25	$3M	$2M	-$4M
Q2 25	$4M	$2M	-$5M
Q3 25	$7M	$4M	-$4M

Valuation

Quarter	P/S	P/E
Q3 20	8.4x	—
Q4 20	7.4x	—
Q1 21	9.7x	—
Q2 21	7.1x	—
Q3 21	5.7x	—
Q3 22	0.9x	—
Q2 23	0.9x	—
Q3 23	0.6x	—
Q4 23	1.5x	—
Q1 24	0.8x	—
Q2 24	1.1x	—
Q3 24	1.2x	—
Q4 24	2.0x	—
Q1 25	1.3x	—
Q2 25	1.9x	—
Q3 25	1.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	-$624.6K	-$636.6K
Q4 20	-$4M	-$4M
Q1 21	-$4M	-$4M
Q2 21	-$4M	-$5M
Q3 21	-$4M	-$4M
Q3 22	-$6M	-$6M
Q2 23	-$3M	-$3M
Q3 23	-$3M	-$3M
Q4 23	-$3M	-$3M
Q1 24	-$3M	-$3M
Q2 24	-$3M	-$3M
Q3 24	-$4M	-$4M
Q4 24	-$3M	-$3M
Q1 25	-$4M	-$4M
Q2 25	-$3M	-$4M
Q3 25	-$4M	-$3M

Capital Expenditures

Quarter	CapEx
Q3 20	$12.0K
Q4 20	$95.2K
Q1 21	$261.7K
Q2 21	$1M
Q3 21	$440.5K
Q3 22	$100.0K
Q2 23	$245.0K
Q3 23	$154.0K
Q4 23	$165.0K
Q1 24	$151.0K
Q2 24	$60.0K
Q3 24	$211.0K
Q4 24	$165.0K
Q1 25	$122.0K
Q2 25	$771.0K
Q3 25	$893.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	-0.7%	-19.8%
Q4 20	+8.2%	+71.1%
Q1 21	+7.9%	+19.1%
Q2 21	+37.5%	+82.5%
Q3 21	+38.1%	+96.7%
Q3 22	+28.4%	+1.0%
Q2 23	-1.5%	+15.4%
Q3 23	-26.6%	-20.7%
Q4 23	-28.6%	-25.0%
Q1 24	-19.5%	-25.4%
Q2 24	+19.4%	-24.3%
Q3 24	+16.9%	-4.2%
Q4 24	+13.9%	-13.6%
Q1 25	-11.8%	-6.2%
Q2 25	-5.8%	+45.0%
Q3 25	+75.7%	+71.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$428.7K	13.0%
Q4 20	$826.3K	25.0%
Q1 21	$434.3K	12.6%
Q2 21	$648.1K	14.4%
Q3 21	$1M	24.5%
Q3 22	$350.0K	8.2%
Q2 23	$459.0K	13.5%
Q3 23	$189.0K	5.7%
Q4 23	$152.0K	4.7%
Q1 24	$299.0K	8.7%
Q2 24	$270.0K	6.7%
Q3 24	$142.0K	3.7%
Q4 24	$57.0K	1.5%
Q1 25	$317.0K	10.5%
Q2 25	$242.0K	6.3%
Q3 25	$55.0K	0.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 20	—	$4M	$431.7K
Q4 20	—	$5M	$820.3K
Q1 21	—	$5M	$860.2K
Q2 21	—	$6M	$1M
Q3 21	—	$7M	$2M
Q3 22	—	$7M	$1M
Q2 23	$100.0K	$6M	$590.0K
Q3 23	$100.0K	$5M	$641.0K
Q4 23	$100.0K	$5M	$606.0K
Q1 24	$100.0K	$5M	$655.0K
Q2 24	—	$4M	$320.0K
Q3 24	—	$4M	$346.0K
Q4 24	$100.0K	$4M	$412.0K
Q1 25	—	$5M	$358.0K
Q2 25	—	$6M	$260.0K
Q3 25	—	$8M	$403.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$24M	$0	$24M
Q1 22	$18M	$0	$18M
Q2 22	$13M	$0	$13M
Q3 22	$7M	$0	$7M
Q4 22	$4M	$0	$4M
Q1 23	$7M	$0	$7M
Q2 23	$4M	$0	$4M
Q3 23	$988.0K	$0	$988.0K
Q4 23	$2M	$0	$2M
Q1 24	$3M	$0	$3M
Q2 24	$7M	$0	$7M
Q3 24	$6M	$0	$6M
Q4 24	$6M	$0	$6M
Q1 25	$2M	$0	$2M
Q2 25	$4M	$0	$4M
Q3 25	$3M	$0	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	500K	+0.0%	+0.8%
Q4 20	552K	+10.5%	+11.1%
Q1 21	728K	+31.9%	+46.0%
Q2 21	830K	+13.9%	+66.1%
Q3 21	833K	+0.4%	+66.8%
Q3 22	849K	+2.0%	+53.8%
Q2 23	1M	+41.0%	+64.3%
Q3 23	1M	+0.0%	+44.3%
Q4 23	2M	+53.2%	+120.1%
Q1 24	2M	+25.9%	+171.8%
Q2 24	3M	+39.9%	+169.7%
Q3 24	7M	+104.9%	+452.5%
Q4 24	6M	-11.0%	+221.2%
Q1 25	9M	+45.9%	+272.4%
Q2 25	9M	+5.7%	+181.5%
Q3 25	11M	+20.6%	+65.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	—	—
Q4 20	$35.6K	93
Q1 21	$37.1K	93
Q2 21	$48.4K	93
Q3 21	$48.9K	93
Q3 22	$26.9K	158
Q2 23	$22.0K	154
Q3 23	$21.4K	154
Q4 23	$28.5K	114
Q1 24	$30.0K	114
Q2 24	$35.6K	114
Q3 24	$33.9K	114
Q4 24	$33.9K	109
Q1 25	$27.7K	109
Q2 25	$35.0K	109
Q3 25	$62.2K	109

Revenue / Employee